搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按相关度排序
按时间排序
13 小时
DATROWAY® Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive ...
DATROWAY Approved in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer ...
Great Pet Care on MSN
15 小时
Denamarin For Dogs: A Comprehensive Review
When my 8-year-old Cocker Spaniel visited the veterinarian for a routine checkup, I wasn’t expecting any problems. However, ...
WLKY Louisville on MSN
3 天
How Fizz District, Frankfort Avenue's new drink spot, is changing the soda game
While house-made sodas are the main attraction at Fizz District, the menu also features several zero-proof cocktails and a selection of seltzers.
Medscape
13 小时
FDA Approves New ADC for HR+, HER2- Breast Cancer
The US Food and Drug Administration (FDA) has approved datopotamab deruxtecan for the treatment of certain patients with ...
来自MSN
13 小时
Best Liver Supplements for Cats: Supporting Your Feline’s Liver Health
Maintaining liver health in cats is crucial for their overall well-being. The liver is an essential organ that detoxifies the ...
2 天
Incyte And Syndax Announce U.S. Food And Drug Administration (FDA) Approval Of Niktimvotm ...
U.S. launch expected in early February – – Niktimvo is the first and only approved treatment for chronic GVHD that targets CSF-1R to reduce the drive ...
MarketWatch
1 天
E-Mini S&P 500 Future Continuous Contract
2-Year U.S. Treasury Note Continuous Contract $102.797-0.008-0.01% 5-Year U.S. Treasury Note Continuous Contract $106.227-0.039-0.04% 10-Year U.S. Treasury Note Continuous Contract $108.547-0.063 ...
4 天
Agios Announces Key 2025 Milestones for Innovative Rare Disease Portfolio
FDA Accepted Agios’ Supplemental New Drug Application for PYRUKYND® (mitapivat) in Adult Patients with Non-Transfusion-Dependent and ...
Pharm Exec
1 天
FDA Approves Incyte and Syndax’s Niktimvo for Chronic Graft-Versus-Host Disease in 9 and ...
Niktimvo marks the first FDA-approved therapy targeting CSF-1R to address inflammation and fibrosis in chronic ...
Targeted Oncology
17 小时
FDA Approves Dato-DXd in HR+/HER2– Breast Cancer
As supported by data from the phase 3 TROPION-Breast01 trial, datopotamab deruxtecan is now an FDA-approved treatment for ...
Armed robbery in Revesby
23 小时
Real-World Study: Tenofovir Amibufenamide for Hep B
Chronic hepatitis B (CHB) remains a significant global health challenge, and effective antiviral therapies are essential for long-term management ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈